Trial Profile
A Multicenter, Open-Label, Phase I Study of MK-0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 21 Aug 2012 Actual end date changed from Aug 2011 to Apr 2012 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Actual patients number is 9 as reported by ClinicalTrials.gov.
- 09 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.